Entia Biosciences, Inc. (ERGO)

Market Cap	3.41K -98.5%
Revenue (ttm)	265.47K -23.5%
Net Income	-1.40M
EPS	-0.05
Shares Out	34.06M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,000
Average Volume	16,021
Open	0.0001
Previous Close	0.0403
Day's Range	0.0001 - 0.0001
52-Week Range	0.0001 - 0.0403
Beta	26.12
RSI	47.67
Earnings Date	n/a

About Entia Biosciences

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical food, nutraceutical...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 7
• Stock Exchange: OTCMKTS
• Ticker Symbol: ERGO

Financial Performance

In 2016, Entia Biosciences's revenue was $265,466, a decrease of -23.48% compared to the previous year's $346,910. Losses were -$1.40 million, -38.24% less than in 2015.